PeptideCompareCartalax — EU research guide.
Cartalax is a synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator series targeting cartilage, kidney and fibroblast function. It belongs to the same ultra-short peptide bioregulator class as Vilon and Crystagen, which PeptideCompare already covers.
What is Cartalax?
Cartalax is a synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator series targeting cartilage, kidney and fibroblast function. It belongs to the same ultra-short peptide bioregulator class as Vilon and Crystagen, which PeptideCompare already covers.
What does the research show?
Research is concentrated in cartilage-aging and connective-tissue models, with Eastern European groups reporting effects on chondrocyte and fibroblast gene expression. No independently replicated human trials are publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Sold by a small number of specialist vendors for laboratory connective-tissue research only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and declines as potency is lost. Above the dotted 80% line the material is considered reliable — hover the chart for exact values.
⚠ Estimates modelled per component from molecular properties (chain length, cyclisation, oxidation- and deamidation-sensitive residues, light sensitivity). Indicative only — not lab-measured per batch.
Cartalax across EU suppliers
COA-verified EU vendors · Updated monthly